News - Kadcyla


Current filters:


Popular Filters

UK’s NICE rejects use of Roche’s Kadcyla for breast cancer on NHS


UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has today issued preliminary…

KadcylaNorthern EuropeOncologyPharmaceuticalPricingRegulationRocheUK

Germany’s IQWiG views Xofigo, Kadcyla and Eviplera


In an early benefit assessment under the Act on the Reform of the Market for Medicinal Products, the…

Anti-viralsBayerEvipleraGermanyGilead SciencesKadcylaNorthern EuropeOncologyPharmaceuticalPricingRegulationRocheXofigo

Synthon’s SYD985 may broaden target population of cancer patients


Dutch generic drugs company Synthon Biopharmaceuticals has released the results of a head-to-head comparative…

KadcylaOncologyPharmaceuticalResearchRocheSYD985Synthon Biopharmaceuticals

Roche’s breast cancer drug Kadcyla debuts in UK

Roche’s breast cancer drug Kadcyla debuts in UK


Swiss drug major Roche’s Kadcyla (ado-trastuzumab emtansine or T-DM1) is now available for UK patients…

KadcylaMarkets & MarketingNorthern EuropeOncologyPharmaceuticalRocheUK

Roche’s Kadcyla approved in the EU for advanced HER2-positive breast cancer

Roche’s Kadcyla approved in the EU for advanced HER2-positive breast cancer


Swiss drug major Roche says that Kadcyla (ado-trastuzumab emtansine or T-DM1), the latest targeted medicine…


Japan NHI price listing for Chugai’s Kadcyla delayed


Japanese drugmaker Chugai Pharmaceutical, which is majority owned by Swiss major Roche, says that the…

Asia-PacificChugai PharmaceuticalKadcylaOncologyPharmaceuticalPricingResearchRoche

Roche investing 800 million Swiss francs to expand biologics production

Roche investing 800 million Swiss francs to expand biologics production


Roche said this morning it plans to invest 800 million Swiss francs ($879.2 million) within its global…

BiotechnologyEuropeFinancialGenentechKadcylaNorth AmericaPerjetaProductionRoActemraRoche

Roche highlights late-stage pipeline beyond cancer


Swiss drug major Roche has provided an update from its leading late-stage pipeline comprising 10 new…


Highlights from European Cancer Congress on Kadcyla, Yervoy, Erbitux and Somatuline


A host of new oncology data was presented at the European Cancer Congress in Amsterdam, the Netherlands,…

Bristol-Myers SquibbErbituxEuropeIpsenKadcylaMerck KGaAOncologyPharmaceuticalResearchRocheSomatulineYervoy

CHMP positive decision for Kadcyla, and approval in Japan


The cancer drug Kadcyla (trastuzumab emtansine) has today received a positive opinion from the European…


FDA advisory panel backs new indication for Genentech's Perjeta


The US Food and Drug Administration's Oncologic Drugs Advisory Committee (ODAC) yesterday (September…

BiotechnologyGenentechKadcylaNorth AmericaOncologyPerjetaPharmaceuticalRegulationRoche

Roche hopes Kadcyla will replace revenue lost by Herceptin patent expiry


Swiss drug major Roche (ROG: SIX) could be hit by biosimilar versions of its breakthrough HER2-positive…


US FDA approves Roche's late-stage breast cancer drug Kadcyla


The US Food and Drug Administration on Friday approved Kadcyla (ado-trastuzumab emtansine), a new therapy…

BiotechnologyGenentechImmunoGenKadcylaNorth AmericaOncologyPharmaceuticalRegulationRochetrastuzumab emtansine

Growing patient population to drive Mexican breast cancer market


An expanding patient population will largely contribute to the growth of the market for treating breast…

AfinitorEisaiHalavenKadcylaMarkets & MarketingNovartisOncologyPerjetaPharmaceuticalRocheSouth Americatrastuzumab emtansine

Back to top